Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker

Breast Cancer Research

Volumn 14, Issue 1, 2012, Pages

  Johansson, Ida ^a   Nilsson, Cecilia ^b,c   Berglund, Pontus ^a   Lauss, Martin ^a   Ringnér, Markus ^a   Olsson, Håkan ^a   Luts, Lena ^d   Sim, Edith ^e   Thorstensson, Sten ^f   Fjällskog, Marie Louise ^c   Hedenfalk, Ingrid ^a  

^a LUND UNIVERSITY   (Sweden)

^b CENTRAL HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; ESTROGEN RECEPTOR; N ACETYLTRANSFERASE 1; UNCLASSIFIED DRUG; ARYLAMINE ACETYLTRANSFERASE; ISOENZYME; N-ACETYLTRANSFERASE 1; TRANSCRIPTOME; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; FEMALE; FEMALE BREAST CANCER; GENE EXPRESSION; GENE EXPRESSION PROFILING; HLA SYSTEM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MALE BREAST CANCER; OUTCOME ASSESSMENT; SURVIVAL; TISSUE MICROARRAY; BREAST TUMOR; CLASSIFICATION; CLUSTER ANALYSIS; COMPARATIVE STUDY; DNA MICROARRAY; ENZYMOLOGY; GENETICS; INTRADUCTAL CARCINOMA; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NONPARAMETRIC TEST; PAGET NIPPLE DISEASE; PRINCIPAL COMPONENT ANALYSIS; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ARYLAMINE N-ACETYLTRANSFERASE; BREAST NEOPLASMS, MALE; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; ISOENZYMES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRINCIPAL COMPONENT ANALYSIS; PROGNOSIS; STATISTICS, NONPARAMETRIC; TISSUE ARRAY ANALYSIS; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84856991626     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3116     Document Type: Article

References (57)

1. Engholm G, Ferlay J, Christensen N, Bray F, Gjerstorff ML, Klint T, Køtlum JE, Ólafsdóttir E, Pukkala E, Storm HH. NORDCAN: Cancer Incidence, Mortality, Prevalence and Prediction in the Nordic Countries. Acta Oncologica 2009, 49:532-544.
2. Giordano SH. A review of the diagnosis and management of male breast cancer. Oncologist 2005, 10:471-479. 10.1634/theoncologist.10-7-471, 16079314.
3. Agrawal A, Ayantunde AA, Rampaul R, Robertson JF. Male breast cancer: a review of clinical management. Breast Cancer Res Treat 2007, 103:11-21. 10.1007/s10549-006-9356-z, 17033919.
4. Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, Bartlett JM, Gelmon K, Nahleh Z, Bergh J, Cutuli B, Pruneri G, McCaskill-Stevens W, Gralow J, Hortobagyi G, Cardoso F. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol 2010, 28:2114-2122. 10.1200/JCO.2009.25.5729, 2860409, 20308661.
5. Rudlowski C, Friedrichs N, Faridi A, Fuzesi L, Moll R, Bastert G, Rath W, Buttner R. Her-2/neu gene amplification and protein expression in primary male breast cancer. Breast Cancer Res Treat 2004, 84:215-223. 10.1023/B:BREA.0000019953.92921.7e, 15026619.
6. Nilsson C, Johansson I, Ahlin C, Thorstensson S, Amini RM, Holmqvist M, Hedenfalk I, Fjällskog M-L. Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact. Submitted.
7. Ottini L, Rizzolo P, Zanna I, Falchetti M, Masala G, Ceccarelli K, Vezzosi V, Gulino A, Giannini G, Bianchi S, Sera F, Palli D. BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy. Breast Cancer Res Treat 2009, 116:577-586. 10.1007/s10549-008-0194-z, 18819001.
8. Brinton LA, Richesson DA, Gierach GL, Lacey JV, Park Y, Hollenbeck AR, Schatzkin A. Prospective evaluation of risk factors for male breast cancer. J Natl Cancer Inst 2008, 100:1477-1481. 10.1093/jnci/djn329, 2720728, 18840816.
9. Nilsson C, Holmqvist M, Bergkvist L, Hedenfalk I, Lambe M, Fjällskog M-L. Similarities and differences in the characteristics and treatment of breast cancer in men and women-a population based study (Sweden). Acta Oncol 2011, 50:1083-1088. 10.3109/0284186X.2011.602114, 21830994.
10. Anderson WF, Devesa SS. In situ male breast carcinoma in the Surveillance, Epidemiology, and End Results database of the National Cancer Institute. Cancer 2005, 104:1733-1741. 10.1002/cncr.21353, 16138363.
11. Thalib L, Hall P. Survival of male breast cancer patients: Population-based cohort study. Cancer Sci 2008, 100(2):292-295.
12. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: a population-based study. Cancer 2004, 101:51-57. 10.1002/cncr.20312, 15221988.
13. Giordano SH. Male breast cancer: it's time for evidence instead of extrapolation. Onkologie 2008, 31:505-506.
14. Johansson I, Nilsson C, Berglund P, Strand C, Jonsson G, Staaf J, Ringner M, Nevanlinna H, Barkardottir RB, Borg A, Olsson H, Luts L, Fjallskog ML, Hedenfalk I. High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer. Breast Cancer Res Treat 2011, 129:747-760. 10.1007/s10549-010-1262-8, 21113657.
15. Callari M, Cappelletti V, De Cecco L, Musella V, Miodini P, Veneroni S, Gariboldi M, Pierotti MA, Daidone MG. Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer. Breast Cancer Res Treat 2011, 127:601-610. 10.1007/s10549-010-1015-8, 20625818.
16. Lehmann U, Streichert T, Otto B, Albat C, Hasemeier B, Christgen H, Schipper E, Hille U, Kreipe HH, Langer F. Identification of differentially expressed microRNAs in human male breast cancer. BMC Cancer 2010, 10:109. 10.1186/1471-2407-10-109, 2850898, 20331864.
17. Fassan M, Baffa R, Palazzo JP, Lloyd J, Crosariol M, Liu CG, Volinia S, Alder H, Rugge M, Croce CM, Rosenberg A. MicroRNA expression profiling of male breast cancer. Breast Cancer Res 2009, 11:R58. 10.1186/bcr2348, 2750120, 19664288.
18. Tommasi S, Mangia A, Iannelli G, Chiarappa P, Rossi E, Ottini L, Mottolese M, Zoli W, Zuffardi O, Paradiso A. Gene copy number variation in male breast cancer by aCGH. Anal Cell Pathol (Amst) 2010, 33(3):113-119.
19. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
20. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
21. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, Liu Y, Nanda R, Tretiakova M, Ruiz Orrico A, Dreher D, Palazzo JP, Perreard L, Nelson E, Mone M, Hansen H, Mullins M, Quackenbush JF, Ellis MJ, Olopade OI, Bernard PS, Perou CM. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006, 7:96. 10.1186/1471-2164-7-96, 1468408, 16643655.
22. Jonsson G, Staaf J, Vallon-Christersson J, Ringner M, Holm K, Hegardt C, Gunnarsson H, Fagerholm R, Strand C, Agnarsson BA, Kilpivaara O, Luts L, Heikkila P, Aittomaki K, Blomqvist C, Loman N, Malmstrom P, Olsson H, Johannsson OT, Arason A, Nevanlinna H, Barkardottir RB, Borg A. Genomic subtypes of breast cancer identified by array comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Res 2010, 12:R42. 10.1186/bcr2596, 2917037, 20576095.
23. Vallon-Christersson J, Nordborg N, Svensson M, Hakkinen J. BASE--2nd generation software for microarray data management and analysis. BMC Bioinformatics 2009, 10:330. 10.1186/1471-2105-10-330, 2768720, 19822003.
24. The R Project for Statistical Computing. , http://www.r-project.org
25. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007, 8:118-127.
26. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002, 30:207-210. 10.1093/nar/30.1.207, 99122, 11752295.
27. Shimodaira H. Approximately unbiased tests of regions using multistep-multiscale bootstrap resampling. Ann Stat 2004, 32(6):26.
28. Lindgren D, Frigyesi A, Gudjonsson S, Sjodahl G, Hallden C, Chebil G, Veerla S, Ryden T, Mansson W, Liedberg F, Hoglund M. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 2010, 70:3463-3472. 10.1158/0008-5472.CAN-09-4213, 20406976.
29. Barbosa-Morais NL, Dunning MJ, Samarajiwa SA, Darot JF, Ritchie ME, Lynch AG, Tavare S. A re-annotation pipeline for Illumina BeadArrays: improving the interpretation of gene expression data. Nucleic Acids Res 2010, 38:e17. 10.1093/nar/gkp942, 2817484, 19923232.
30. Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003, 4:P3. 10.1186/gb-2003-4-5-p3, 12734009.
31. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4:44-57.
32. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M, Sotiriou C. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008, 14:5158-5165. 10.1158/1078-0432.CCR-07-4756, 18698033.
33. Stam NJ, Vroom TM, Peters PJ, Pastoors EB, Ploegh HL. HLA-A- and HLA-B-specific monoclonal antibodies reactive with free heavy chains in western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryo-immuno-electron microscopy. Int Immunol 1990, 2:113-125. 10.1093/intimm/2.2.113, 2088481.
34. Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 1986, 137:2299-2306.
35. Stanley LA, Copp AJ, Pope J, Rolls S, Smelt V, Perry VH, Sim E. Immunochemical detection of arylamine N-acetyltransferase during mouse embryonic development and in adult mouse brain. Teratology 1998, 58:174-182. 10.1002/(SICI)1096-9926(199811)58:5<174::AID-TERA3>3.0.CO;2-Q, 9839355.
36. Stanley LA, Coroneos E, Cuff R, Hickman D, Ward A, Sim E. Immunochemical detection of arylamine N-acetyltransferase in normal and neoplastic bladder. J Histochem Cytochem 1996, 44:1059-1067. 10.1177/44.9.8773572, 8773572.
37. Suzuki R, Shimodaira H. Pvclust: an R package for assessing the uncertainty in hierarchical clustering. Bioinformatics 2006, 22:1540-1542. 10.1093/bioinformatics/btl117, 16595560.
38. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674. 10.1016/j.cell.2011.02.013, 21376230.
39. Shah N, Sukumar S. The Hox genes and their roles in oncogenesis. Nat Rev Cancer 2010, 10:361-371. 10.1038/nrc2826, 20357775.
40. Wu X, Chen H, Parker B, Rubin E, Zhu T, Lee JS, Argani P, Sukumar S. HOXB7, a homeodomain protein, is overexpressed in breast cancer and confers epithelial-mesenchymal transition. Cancer Res 2006, 66:9527-9534. 10.1158/0008-5472.CAN-05-4470, 17018609.
41. Kornegoor R, Verschuur-Maes AH, Buerger H, Hogenes MC, de Bruin PC, Oudejans JJ, van der Groep P, Hinrichs B, van Diest PJ. Molecular subtyping of male breast cancer by immunohistochemistry. Mod Pathol 2012, 25:398-404. 10.1038/modpathol.2011.174, 22056953.
42. Ge Y, Sneige N, Eltorky MA, Wang Z, Lin E, Gong Y, Guo M. Immunohistochemical characterization of subtypes of male breast carcinoma. Breast Cancer Res 2009, 11:R28. 10.1186/bcr2258, 2716496, 19442295.
43. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 2007, 8:R157. 10.1186/gb-2007-8-8-r157, 2374988, 17683518.
44. Teschendorff AE, Caldas C. A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer. Breast Cancer Res 2008, 10:R73. 10.1186/bcr2138, 2575547, 18755024.
45. Staaf J, Ringner M, Vallon-Christersson J, Jonsson G, Bendahl PO, Holm K, Arason A, Gunnarsson H, Hegardt C, Agnarsson BA, Luts L, Grabau D, Ferno M, Malmstrom PO, Johannsson OT, Loman N, Barkardottir RB, Borg A. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol 2010, 28:1813-1820. 10.1200/JCO.2009.22.8775, 20231686.
46. Shaaban AM, Ball GR, Brannan RA, Cserni G, Benedetto AD, Dent J, Fulford L, Honarpisheh H, Jordan L, Jones JL, Kanthan R, Maraqa L, Litwiniuk M, Mottolese M, Pollock S, Provenzano E, Quinlan PR, Reall G, Shousha S, Stephens M, Verghese ET, Walker RA, Hanby AM, Speirs V. A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences. Breast Cancer Res Treat 2011,
47. Jin K, Kong X, Shah T, Penet MF, Wildes F, Sgroi DC, Ma XJ, Huang Y, Kallioniemi A, Landberg G, Bieche I, Wu X, Lobie PE, Davidson NE, Bhujwalla ZM, Zhu T, Sukumar S. The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proc Natl Acad Sci USA 2011,
48. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, Perou CM. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008, 109:123-139. 10.1007/s10549-007-9632-6, 2443103, 17578664.
49. Gudmundsdottir I, Gunnlaugur Jonasson J, Sigurdsson H, Olafsdottir K, Tryggvadottir L, Ogmundsdottir HM. Altered expression of HLA class I antigens in breast cancer: association with prognosis. Int J Cancer 2000, 89:500-505. 10.1002/1097-0215(20001120)89:6<500::AID-IJC6>3.0.CO;2-#, 11102894.
50. Karre K. Express yourself or die: peptides, MHC molecules, and NK cells. Science 1995, 267:978-979. 10.1126/science.7863341, 7863341.
51. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997, 18:89-95. 10.1016/S0167-5699(96)10075-X, 9057360.
52. Wakefield L, Robinson J, Long H, Ibbitt JC, Cooke S, Hurst HC, Sim E. Arylamine N-acetyltransferase 1 expression in breast cancer cell lines: a potential marker in estrogen receptor-positive tumors. Genes Chromosomes Cancer 2008, 47:118-126. 10.1002/gcc.20512, 17973251.
53. Tozlu S, Girault I, Vacher S, Vendrell J, Andrieu C, Spyratos F, Cohen P, Lidereau R, Bieche I. Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr Relat Cancer 2006, 13:1109-1120. 10.1677/erc.1.01120, 17158757.
54. Adam PJ, Berry J, Loader JA, Tyson KL, Craggs G, Smith P, De Belin J, Steers G, Pezzella F, Sachsenmeir KF, Stamps AC, Herath A, Sim E, O'Hare MJ, Harris AL, Terrett JA. Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro. Mol Cancer Res 2003, 1:826-835.
55. Dolled-Filhart M, Ryden L, Cregger M, Jirstrom K, Harigopal M, Camp RL, Rimm DL. Classification of breast cancer using genetic algorithms and tissue microarrays. Clin Cancer Res 2006, 12:6459-6468. 10.1158/1078-0432.CCR-06-1383, 17085660.
56. Bieche I, Girault I, Urbain E, Tozlu S, Lidereau R. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma. Breast Cancer Res 2004, 6:R252-263. 10.1186/bcr784, 400681, 15084249.
57. Butcher NJ, Arulpragasam A, Minchin RF. Proteasomal degradation of N-acetyltransferase 1 is prevented by acetylation of the active site cysteine: a mechanism for the slow acetylator phenotype and substrate-dependent down-regulation. J Biol Chem 2004, 279:22131-22137. 10.1074/jbc.M312858200, 15039438.